DTC
SLN

Deep Track Capital’s Silence Therapeutics SLN Stock Holding History

Deep Track Capital’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,000,000
Closed -$18.2M – 79
2024
Q3 		$18.2M Sell
1,000,000
-359,745
-26% -$6.69M 0.58% 46
2024
Q2 		$25.8M Sell
1,359,745
-284,136
-17% -$6.04M 0.77% 40
2024
Q1 		$35.5M Sell
1,643,881
-307,699
-16% -$6.69M 1.02% 39
2023
Q4 		$33.9M Hold
1,951,580
– – 1.13% 35
2023
Q3 		$19.2M Hold
1,951,580
– – 0.74% 40
2023
Q2 		$10.7M Hold
1,951,580
– – 0.5% 39
2023
Q1 		$12.1M Hold
1,951,580
– – 0.5% 45
2022
Q4 		$29.8M Hold
1,951,580
– – 1.25% 29
2022
Q3 		$19.6M Buy
1,951,580
+1,000,000
+105% +$10.5M 0.9% 42
2022
Q2 		$11.3M Hold
951,580
– – 0.74% 37
2022
Q1 		$18.1M Buy
951,580
+782
+0.1% +$15.6K 1.16% 28
2021
Q4 		$22.7M Buy
+950,798
New +$22M 1.6% 25

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Deep Track Capital's SLN Position: Q4 2024 in Review

Deep Track Capital sold out of Silence Therapeutics (SLN) in Q4 2024, closing a stake of 1,000,000 shares — an estimated $18.2M sold.

Deep Track Capital first reported a position in SLN in Q4 2021 and held it in 12 quarters. The position peaked at $35.5M in Q1 2024. 65 funds tracked by Wall St. Rank hold SLN as of Q4 2024.

  • Deep Track Capital reported no remaining Silence Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Deep Track Capital sold 1,000,000 Silence Therapeutics shares in Q4 2024, an estimated $18.2M.
  • Deep Track Capital first reported a position in Silence Therapeutics in Q4 2021 and held it in 12 quarters.
  • Deep Track Capital's Silence Therapeutics position peaked at $35.5M in Q1 2024.
  • 65 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2024.

Based on Deep Track Capital's 13F filing for Q4 2024, filed 14 Feb 2025.